<!DOCTYPE html>
<html lang="en">
<head>
  
  
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    
    
    <link rel="canonical" href="https://jzpero.github.io/mednotes/Respirology/Interstitial%20Lung%20Disease/Cryptogenic%20Organizing%20Pneumonia/">
    <link rel="shortcut icon" href="../../../img/favicon.ico">
    <meta name="viewport" content="width=device-width, initial-scale=1.0, maximum-scale=1.0, user-scalable=0" />
    <title>Cryptogenic Organizing Pneumonia - MedNotes</title>
    <link href="../../../css/bootstrap-3.3.7.min.css" rel="stylesheet">
    <link href="../../../css/font-awesome-4.7.0.css" rel="stylesheet">
    <link href="../../../css/base.css" rel="stylesheet">
    <link rel="stylesheet" href="../../../css/highlight.css">
    <!-- HTML5 shim and Respond.js IE8 support of HTML5 elements and media queries -->
    <!--[if lt IE 9]>
        <script src="https://oss.maxcdn.com/libs/html5shiv/3.7.0/html5shiv.js"></script>
        <script src="https://oss.maxcdn.com/libs/respond.js/1.3.0/respond.min.js"></script>
    <![endif]-->

    <script src="../../../js/jquery-3.2.1.min.js"></script>
    <script src="../../../js/bootstrap-3.3.7.min.js"></script>
    <script src="../../../js/highlight.pack.js"></script>
    
    <base target="_top">
    <script>
      var base_url = '../../..';
      var is_top_frame = false;
        
        var pageToc = [
          {title: "Variants", url: "#_top", children: [
          ]},
          {title: "Epidemiology and Pathophysiology", url: "#epidemiology-and-pathophysiology", children: [
          ]},
          {title: "Secondary Causes of Organizing Pneumonia", url: "#secondary-causes-of-organizing-pneumonia", children: [
          ]},
          {title: "Clinical Presentation", url: "#clinical-presentation", children: [
          ]},
          {title: "Evaluation", url: "#evaluation", children: [
              {title: "Noninvasive Tests", url: "#noninvasive-tests" },
              {title: "Invasive Tests", url: "#invasive-tests" },
              {title: "Differential Diagnosis", url: "#differential-diagnosis" },
          ]},
          {title: "Management", url: "#management", children: [
              {title: "Steroids", url: "#steroids" },
              {title: "Relapses", url: "#relapses" },
              {title: "Other Therapies", url: "#other-therapies" },
          ]},
          {title: "Prognosis", url: "#prognosis", children: [
          ]},
          {title: "References", url: "#references", children: [
          ]},
        ];

    </script>
    <script src="../../../js/base.js"></script> 
</head>

<body>
<script>
if (is_top_frame) { $('body').addClass('wm-top-page'); }
</script>



<div class="container-fluid wm-page-content">
  <a name="_top"></a>
    

    
    
      
    

  <div class="row wm-article-nav-buttons" role="navigation" aria-label="navigation">
    
    <div class="wm-article-nav pull-right">
      <a href="../Hypersensitivity%20Pneumonitis/" class="btn btn-xs btn-default pull-right">
        Next
        <i class="fa fa-chevron-right" aria-hidden="true"></i>
      </a>
      <a href="../Hypersensitivity%20Pneumonitis/" class="btn btn-xs btn-link">
        Hypersensitivity Pneumonitis
      </a>
    </div>
    
    <div class="wm-article-nav">
      <a href="../../Airway%20Disease/Samter%27s%20Triad/" class="btn btn-xs btn-default pull-left">
        <i class="fa fa-chevron-left" aria-hidden="true"></i>
        Previous</a><a href="../../Airway%20Disease/Samter%27s%20Triad/" class="btn btn-xs btn-link">
        Samter's Triad
      </a>
    </div>
    
  </div>

    

    <p>OP is a pattern of repair after injury; it can be cryptogenic or a response to a specific lung injury. COP has no identifying cause and is under the umbrella of <a href="Interstitial%20Lung%20Disease#Idiopathic%20Interstitial%20Pneumonias%20(IIPs)">Interstitial Lung Disease &gt; Idiopathic Interstitial Pneumonias (IIPs)</a>. It is formerly called <strong>bronchiolitis obliterans organizing pneumonia (BOOP)</strong>. Often misdiagnosed, and can be very responsive to treatment.</p>
<p>Secondary forms of OP are due to a specific cause (infection, drug toxicity, inhalation injury, radiation, cancer) or within another clinical context (CTD, aspiration, transplantation, interstitial pneumonia).</p>
<h2 id="variants">Variants</h2>
<ul>
<li>Focal organizing pneumonia (&lt;15%) which must be distinguished from lung cancer. Might be resectable.</li>
<li>Fulminant COP. First rule out infection then consider IV steroids. High mortality rate from respiratory failure.</li>
<li>Cicatricial OP.</li>
<li>Acute fibrinous OP. Patchy infiltration.</li>
</ul>
<h1 id="epidemiology-and-pathophysiology">Epidemiology and Pathophysiology</h1>
<ul>
<li>COP reasonably rare; 7 per 100,000 hospital admissions. 5-10% of ILD diagnoses. Mean age is 50-60, men &gt; women. About 50% smokers.</li>
<li>Poorly defined pathogenesis. Lung injury occurs as a single event and causes an inflammatory and fibroproliferative process characterized by intra-alveolar fibroproliferation that is reversaible with therapy.<ul>
<li>Contrasted to other fibrotic processes such as UIP which are not reversible.</li>
<li>Alveolar injury --&gt; inflammatory response --&gt; fibroblast response --&gt; protein dysregulation --&gt; interstitial remodeling</li>
</ul>
</li>
</ul>
<h1 id="secondary-causes-of-organizing-pneumonia">Secondary Causes of Organizing Pneumonia</h1>
<ul>
<li>infection (bacterial, viral, parasitic, fungal)</li>
<li>drugs (amiodarone, nitrofurantoin, bleomycin, MTX, cocaine)</li>
<li>CTD (RA, Sjogren's, myositis, SScl, anti-synthetase syndrome, vasculitis)</li>
<li>Hematologic cancer</li>
<li>Transplantation (lung, liver, BM)</li>
<li>Radiation injury</li>
<li>CVID</li>
<li>Other ILD (eosinophilic pneumonia, hypersensitivity pneumonia, UIP)</li>
<li>IBD</li>
<li>Other<ul>
<li>other lung processes: abscess, DAH, airway obstruction</li>
<li>Inhalation injury</li>
</ul>
</li>
</ul>
<h1 id="clinical-presentation">Clinical Presentation</h1>
<p>Suspect COP when patients with a ?pneumonia do not respond to antibiotic treatment. Symptoms are often subacute and develop over weeks to months:
- dry cough, dyspnea are most common
- influenza-like symptoms are possible (10-15%)
- fever is common (44%)
- hemoptysis is rare (&lt;5%)</p>
<p>Examination reveals inspiratory crackles (60%), rarely clubbing (&lt;3%). Rarely the examination is normal (&lt;5%).</p>
<h1 id="evaluation">Evaluation</h1>
<h2 id="noninvasive-tests">Noninvasive Tests</h2>
<ol>
<li>Lab tests reveal evidence of inflammation. Consider testing for CTDs as COP can precede CTD manifestations by weeks to months.</li>
<li>PFTs show restricted ventilatory defects and a reduced DLCO, but are normal lung volumes in 25% of patients. Obstruction is not a feature of COP. Hypoxemia is common.</li>
<li>Imaging is usually distinctive: bilateral opacities (patchy/diffuse and consolidative or hazy) with normal lung volumes. CT is better than CXR. On CT, the pattern is peripheral and multifocal consolidation +/- bronchograms, with lesions in all lung zones, and slightly predominant subpleural and lower-lung distribution. Other findings:<ol>
<li>GGO</li>
<li>Nodules 8 mm in diameter in a well-defined acinar pattern</li>
<li>Reverse halo pattern (&lt;5%)</li>
</ol>
</li>
</ol>
<h2 id="invasive-tests">Invasive Tests</h2>
<ol>
<li>BAL is recommended if COP is suspected to rule out infection and other disorders (eosinophilic pneumonia, DAH). Typically BAL shows lymphocytic alveolitis with increased neutrophils and eosinophils.</li>
<li>Histopathology is not alway needed to make the diagnosis.</li>
</ol>
<h2 id="differential-diagnosis">Differential Diagnosis</h2>
<ol>
<li>CAP</li>
<li>Hypersensitivity pneumonitis</li>
<li>Eosinophilic penumonia</li>
<li>Alveolar hemorrhage</li>
<li>Vasculitis</li>
<li>Pulmonary lymphoma, invasive mucinous adenocarcinoma</li>
</ol>
<h1 id="management">Management</h1>
<p>Treatment of COP is empirical because no prospective RCTs have been done. Less than 10% of patients have spontaneous improvement, but they typically had milder disease.</p>
<h2 id="steroids">Steroids</h2>
<ul>
<li>systemic steroids are the preferred treatment</li>
<li>Prednisone 0.5 to 1 mg/kg/day up to 60 mg/day, for 2-4 weeks initially then tapered to 0.25 mg/kg/day depending on the clinical response to complete 4-6 months of therapy. Over the next 6 to 12 months the steroids are tapered to zero if the patient's condition allows.<ul>
<li>Clinical improvement should manifest within 1-3 days. First symptoms decrease then radiologic findings improve within 3 months.</li>
<li>PJP ppx recommended for more than 20 mg prednisone per day</li>
</ul>
</li>
<li>Consider pulse steroids (500-1000 mg methylprednisolone for 3-5 days) for sick patients then step down to oral regimen above.</li>
</ul>
<h2 id="relapses">Relapses</h2>
<p>Defined by worsening symptoms or new radiolographic findings during or after steroid treatment. Rare, less than 25% during the first year. Can occur when tapering or stopping therapy too quickly, and generally when prednisone &lt; 15 mg/day.</p>
<p>Associated with delayed diagnosis, delayed treatment, severe disease, traction bronchiectasis, abnormal DLCO, cholestasis, hypoxemia, and advanced fibrosis.</p>
<p>Treat with resuming or increasing steroids, consider &lt;20 mg/d based on studies showing equal efficacy. </p>
<p>Not associated with morbidity or mortality.</p>
<h2 id="other-therapies">Other Therapies</h2>
<p>Considered for those who need additional agents or cannot tolerate steroids:
- Macrolides
- Cytotoxic therapy (AZA, CYC)
- Antimetabolites etc (MMF, CsA, RTX, IVIg)</p>
<h1 id="prognosis">Prognosis</h1>
<p>Generally, COP has an excellent prognosis. Progressive respiratory failure or death are rare (&lt;10%), and 5-year survival rate is &gt;90%. Despite this, of course patients have higher mortality than the general population.</p>
<p>Secondary organizing pneumonia has a slightly worse prognosis, due to the underlying illness.</p>
<h1 id="references">References</h1>
<ol>
<li>King TE, Lee JS. Cryptogenic Organizing Pneumonia. New England Journal of Medicine. 2022;386(11):1058-1069. doi:10.1056/NEJMra2116777</li>
</ol>

  <br>
    

    
    
      
    

  <div class="row wm-article-nav-buttons" role="navigation" aria-label="navigation">
    
    <div class="wm-article-nav pull-right">
      <a href="../Hypersensitivity%20Pneumonitis/" class="btn btn-xs btn-default pull-right">
        Next
        <i class="fa fa-chevron-right" aria-hidden="true"></i>
      </a>
      <a href="../Hypersensitivity%20Pneumonitis/" class="btn btn-xs btn-link">
        Hypersensitivity Pneumonitis
      </a>
    </div>
    
    <div class="wm-article-nav">
      <a href="../../Airway%20Disease/Samter%27s%20Triad/" class="btn btn-xs btn-default pull-left">
        <i class="fa fa-chevron-left" aria-hidden="true"></i>
        Previous</a><a href="../../Airway%20Disease/Samter%27s%20Triad/" class="btn btn-xs btn-link">
        Samter's Triad
      </a>
    </div>
    
  </div>

    <br>
</div>

<footer class="container-fluid wm-page-content">
  <p>Documentation built with <a href="https://www.mkdocs.org/">MkDocs</a> using <a href="https://github.com/gristlabs/mkdocs-windmill">Windmill</a> theme by Grist Labs.</p>
</footer>

</body>
</html>